ArticleMolecular diversity2026
Synthesis and biological evaluation of bisspirooxindole-hexahydroindolizines as potential anticancer agent.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we report an efficient three-component domino reaction of isatin, pipecolic acid, and alkyl 2-(1-methyl-2-oxoindolin-3-ylidene) acetate that provided a simple and convenient route to synthesis of novel methyl-2,2″-dioxo-1',5',6',7',8',8a'-hexahydrodispiro[indoline-3,2'-indolizine-3',3″-indoline]-1'-carboxylate derivatives. This regio- and diastereoselective transformation presumably proceeds through a domino sequence involving azomethine ylide formation followed by a [3 + 2] cycloaddition reaction, leading to the construction of the bisspirooxindole scaffold in a one-pot operation. Preliminary biological evaluation revealed that the synthesized compounds exhibited significant cytotoxic activity against MCF-7 breast cancer cells. The docking study suggested that compound 3d can act as an estrogen receptor alpha (ER-α) modulator, and can be considered a promising lead compound.
Indexed as
Identifiers
42443541What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.